April 17, 2026
QbD Pharmaceutical announced that the company has successfully obtained four drug registration approvals issued by the National Medical Products Administration (NMPA) since January 2026, namely Calcium Gluconate Injection, Magnesium Sulfate Injection, Potassium Chloride Injection, and Calcium Chloride Injection. These consecutive approvals further strengthen the company’s product portfolio in emergency care and electrolyte balance regulation, and reaffirm its strong R&D and industrialization capabilities.
All four approved products are essential basic emergency drugs, widely used in emergency departments, ICUs, obstetrics and gynecology departments, and surgical wards across medical institutions of all levels.
- Calcium Gluconate Injection: A classic calcium supplement for hypocalcemia, acute hypocalcemia, alkalosis, and tetany associated with hypoparathyroidism. It also serves as a specific antidote for magnesium and fluorine poisoning and is used in cardiac resuscitation.
- Magnesium Sulfate Injection: A widely used anticonvulsant and electrolyte supplement. Indicated for hypertension in pregnancy, preeclampsia, eclampsia, premature labor, tetanus convulsions, and magnesium replacement therapy. It is a must-have drug for obstetrics, gynecology, and emergency care.
- Potassium Chloride Injection: A core potassium supplement (high-alert medication) for the treatment and prevention of hypokalemia caused by vomiting, diarrhea, diuretics, prolonged fasting, etc. It is also effective for tachyarrhythmias induced by digitalis poisoning. Its approval underscores the company’s superior manufacturing and quality control in high-risk injections.
- Calcium Chloride Injection: A fast-acting calcium supplement for acute hypocalcemia requiring rapid elevation of serum calcium. It is a critical drug for severe hypocalcemia, magnesium poisoning, and fluorine poisoning.
As a “Specialized, Sophisticated, Unique and New” enterprise focused on high-end injectables, QbD Pharmaceutical is committed to addressing unmet clinical needs. Adhering to international top-tier standards, the company accelerates the R&D and commercialization of more high-quality generics and improved new drugs, delivering safe, effective, and stable products to safeguard public health and advance the high-quality development of China’s pharmaceutical industry.
